Sun Pharmaceuticals Industries Ltd
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market.[1] It is the largest pharmaceutical company in India.[2]
- Market Cap ₹ 2,30,240 Cr.
- Current Price ₹ 960
- High / Low ₹ 1,072 / 790
- Stock P/E 26.7
- Book Value ₹ 233
- Dividend Yield 1.04 %
- ROCE 17.4 %
- ROE 16.6 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 26.4% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 56.0%
Cons
- The company has delivered a poor sales growth of 10.6% over past five years.
- Tax rate seems low
- Working capital days have increased from 104 days to 171 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
8,019 | 11,131 | 16,080 | 27,392 | 28,487 | 31,578 | 26,489 | 29,066 | 32,838 | 33,498 | 38,654 | 43,886 | |
5,047 | 6,346 | 9,078 | 19,498 | 20,313 | 21,476 | 20,858 | 22,689 | 25,855 | 25,028 | 28,397 | 32,239 | |
Operating Profit | 2,972 | 4,784 | 7,003 | 7,894 | 8,174 | 10,102 | 5,631 | 6,377 | 6,983 | 8,470 | 10,258 | 11,647 |
OPM % | 37% | 43% | 44% | 29% | 29% | 32% | 21% | 22% | 21% | 25% | 27% | 27% |
702 | -90 | -1,968 | 283 | -42 | 610 | -135 | -258 | 382 | -3,449 | -3,505 | 463 | |
Interest | 28 | 43 | 44 | 579 | 523 | 400 | 518 | 555 | 303 | 141 | 127 | 172 |
Depreciation | 291 | 336 | 409 | 1,195 | 1,038 | 1,265 | 1,500 | 1,753 | 2,053 | 2,080 | 2,144 | 2,529 |
Profit before tax | 3,355 | 4,315 | 4,581 | 6,403 | 6,571 | 9,048 | 3,479 | 3,810 | 5,010 | 2,799 | 4,481 | 9,408 |
Tax % | 9% | 20% | 15% | 14% | 14% | 13% | 26% | 16% | 16% | 18% | 24% | 9% |
Net Profit | 3,042 | 3,469 | 3,879 | 5,476 | 5,658 | 7,846 | 2,542 | 3,208 | 4,172 | 2,272 | 3,389 | 8,513 |
EPS in Rs | 12.83 | 14.40 | 15.17 | 21.92 | 18.89 | 29.03 | 8.73 | 11.11 | 15.69 | 12.10 | 13.64 | 35.32 |
Dividend Payout % | 17% | 9% | 10% | 14% | 5% | 12% | 23% | 25% | 25% | 62% | 73% | 33% |
Compounded Sales Growth | |
---|---|
10 Years: | 15% |
5 Years: | 11% |
3 Years: | 10% |
TTM: | 14% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | 26% |
3 Years: | 30% |
TTM: | 31% |
Stock Price CAGR | |
---|---|
10 Years: | 6% |
5 Years: | 15% |
3 Years: | 26% |
1 Year: | 12% |
Return on Equity | |
---|---|
10 Years: | 14% |
5 Years: | 12% |
3 Years: | 14% |
Last Year: | 17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
104 | 104 | 207 | 207 | 241 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | |
Reserves | 12,132 | 14,886 | 18,318 | 25,431 | 32,742 | 36,400 | 38,074 | 41,169 | 45,025 | 46,223 | 47,771 | 55,755 |
321 | 260 | 2,561 | 8,996 | 8,497 | 9,832 | 10,385 | 10,514 | 8,315 | 3,869 | 1,290 | 6,886 | |
3,762 | 5,128 | 8,009 | 14,089 | 13,948 | 14,624 | 15,598 | 12,666 | 14,615 | 17,291 | 20,466 | 17,862 | |
Total Liabilities | 16,319 | 20,377 | 29,095 | 48,723 | 55,428 | 61,095 | 64,297 | 64,590 | 68,194 | 67,622 | 69,768 | 80,744 |
3,951 | 5,647 | 6,817 | 12,682 | 15,872 | 17,675 | 18,853 | 21,837 | 22,847 | 21,553 | 22,460 | 28,430 | |
CWIP | 345 | 563 | 842 | 2,039 | 2,175 | 2,801 | 2,465 | 1,411 | 1,220 | 1,567 | 1,287 | 963 |
Investments | 2,213 | 2,412 | 2,786 | 2,716 | 1,830 | 1,192 | 7,143 | 7,903 | 10,143 | 9,612 | 12,849 | 14,830 |
9,810 | 11,756 | 18,650 | 31,286 | 35,550 | 39,427 | 35,837 | 33,439 | 33,984 | 34,890 | 33,173 | 36,520 | |
Total Assets | 16,319 | 20,377 | 29,095 | 48,723 | 55,428 | 61,095 | 64,297 | 64,590 | 68,194 | 67,622 | 69,768 | 80,744 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2,234 | 3,357 | 3,959 | 5,616 | 6,686 | 7,082 | 3,907 | 2,196 | 6,555 | 6,170 | 8,985 | 4,959 | |
-748 | -2,375 | -2,176 | -1,502 | -3,949 | -4,186 | -3,104 | -310 | -2,225 | 407 | -5,556 | -7,944 | |
-544 | -665 | 507 | -1,187 | -1,889 | -2,285 | -1,539 | -2,731 | -5,715 | -5,980 | -5,193 | 2,376 | |
Net Cash Flow | 942 | 316 | 2,290 | 2,927 | 848 | 611 | -736 | -844 | -1,386 | 596 | -1,765 | -608 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 95 | 79 | 50 | 68 | 87 | 83 | 108 | 112 | 105 | 99 | 100 | 95 |
Inventory Days | 464 | 454 | 410 | 307 | 370 | 307 | 338 | 366 | 311 | 378 | 317 | 360 |
Days Payable | 221 | 186 | 174 | 178 | 207 | 197 | 234 | 192 | 142 | 167 | 158 | 194 |
Cash Conversion Cycle | 338 | 347 | 286 | 197 | 251 | 193 | 212 | 285 | 274 | 310 | 259 | 261 |
Working Capital Days | 127 | 111 | 126 | 76 | 104 | 73 | 79 | 137 | 112 | 84 | 56 | 171 |
ROCE % | 28% | 35% | 38% | 25% | 20% | 21% | 10% | 11% | 11% | 14% | 18% | 17% |
Documents
Announcements
- Compliances-Reg.24(A)-Annual Secretarial Compliance 4h
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 8h
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
10h - Press Release relating to 'Sun Pharma Announces China NMPA Approval For ILUMETRI (Tildrakizumab Injection) For Treatment Of Adults with Moderate-To-Severe Plaque Psoriasis', which we shall …
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
16h - Press Release relating to 'Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia …
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 27 May
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Concalls
-
Apr 2023TranscriptNotesPPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022TranscriptPPT
-
Jun 2022TranscriptPPT
-
Mar 2022Transcript PPT
-
Nov 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Jan 2021TranscriptPPT
-
Oct 2020TranscriptPPT
Product Offerings
The company produces a comprehensive and diverse portfolio of generic and specialty medicines targeting wide spectrum of chronic and acute treatments. Its product portfolio includes generics, branded generics, specialty, difficult-to-make technology intensive products, anti-retrovirals, APIs and intermediates.[1] It offers medicines in all form of dosages i.e. injectables, sprays, ointments, creams, liquids, tablets and capsules.[2]